[
  {
    "title": "3 of Goldman Sachs' best investing tips for currently volatile markets",
    "published": 1742563852
  },
  {
    "title": "Merck (NYSE:MRK) Unveils New Data On Cardiovascular Advances At ACC.25 Annual Conference",
    "published": 1742491921
  },
  {
    "title": "Merck Loses Almost $52B in 6 Months: How to Play MRK Stock",
    "published": 1742393460
  },
  {
    "title": "Actinium Pharmaceuticals launches clinical trial for Actimab-A in combination",
    "published": 1742386292
  },
  {
    "title": "Health Canada Approves KEYTRUDA\u00ae for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy",
    "published": 1742382000
  },
  {
    "title": "Merck Data at ACC.25 Highlight Innovative Advancements and Commitment to Improving Outcomes for People Living with Cardiovascular Disease",
    "published": 1742381100
  },
  {
    "title": "Is Merck & Co Inc. (NYSE:MRK) the Most Undervalued S&P 500 Stock to Buy Now?",
    "published": 1742302016
  },
  {
    "title": "Is Merck & Co Inc. (NYSE:MRK) the Most Profitable Value Stock to Buy Now?",
    "published": 1742239948
  },
  {
    "title": "MSD to push for approval of HIV combo after Phase III success",
    "published": 1741870187
  },
  {
    "title": "Merck Plans Regulatory Submission For Two-Drug Regime For HIV Infection By Mid-2025",
    "published": 1741800637
  },
  {
    "title": "Merck Announces Positive Data from Phase 3 Trials that Show the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) Maintained HIV-1 Viral Suppression at Week 48",
    "published": 1741793160
  },
  {
    "title": "Merck (NYSE:MRK) Unveils US$1 Billion Durham Facility For Advanced Vaccine Manufacturing Expansion",
    "published": 1741715235
  }
]